Eli Lilly (LLY) is pursuing an M&A strategy at unprecedented speed and scale, fueled by strong cash flows from its weight-loss and diabetes drugs. The company tends to step in early when asset valuations are low, while not ruling out acquiring late-stage drugs to expand beyond the obesity market. Under the leadership of Ricks, Lilly is focusing on reinvesting in human health rather than traditional shareholder returns, striving to seize opportunities in scientific “white spaces” and lay the foundation for its next phase of growth.
Eli Lilly Chief Executive Officer Dave Ricks recently said investors can expect the company to pursue larger deals, similar to its $7.8 billion acquisition of Centessa Pharmaceuticals Plc, as it searches broadly for assets in scientific “white spaces.” The world’s largest pharmaceutical company is spending aggressively at a record pace, using the hefty profits from its weight-loss and diabetes injectable drugs to expand into new areas that could drive its next phase of growth.
Thanks to Mounjaro, Zepbound injections and the weight-loss drug Foundayo, Lilly’s sales are expected to reach $88 billion this year, nearly double the level of two years ago. Yet the pharmaceutical industry’s brutal cycle never stops—expensive research, high-risk development and short sales windows to recoup investments. Ricks is determined to act early to avoid the spiraling sales declines that once trapped previous industry leaders.
Speaking in an interview on the sidelines of the European Association for the Study of Diabetes annual meeting in Milan, Ricks said the company does not feel a sense of urgency that would force it to strike deals under financial pressure. He called that phenomenon “shopping when you’re hungry,” arguing that it easily leads to mistakes. He highlighted infectious diseases, women’s health and mental illness as areas where Lilly has an opportunity to make an impact. Earlier this year, the company acquired three vaccine makers for as much as $3.8 billion, and recently agreed to buy psychedelics company AtaiBeckley Inc. for roughly the same price.
Ricks said these deals are examples of Lilly “taking a slightly bigger step,” and investors will see more such moves in the future. He noted that the company prefers more mature assets when they can solve entirely new problems. It is understood that Lilly’s Mounjaro and Zepbound still have about a decade of patent protection. The company has historically targeted earlier-stage, relatively lower-priced drugs. Ricks said he prefers to step in before major data readouts and before any bidding process begins.
Still, recent deals show that Lilly is willing to commit more capital to acquiring late-stage drugs as a way to build a competitive advantage in markets beyond obesity. In addition, Ricks has little interest in traditional forms of shareholder capital returns. He said the company faces a choice: use those returns to reinvest in productive areas outside obesity, or buy back shares and pay dividends. In his view, investing in human health is far more interesting.
